Cancer – A Phase 2 Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
Condition or Therapy:
Lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia
What is the goal of this study?
When patients receive a stem cell transplant from a donor they can sometimes develop graft-versus-host disease (GVHD). This happens when the donated T cells attack a patient’s body, including the skin, liver, kidneys, lungs, and other organs.
In this phase 2 trial, researchers want to find out if removing the group of T cells that are responsible for GVHD before they are given to patients will prevent them from getting GVHD.
Who can join the study?
This study might be a good fit for children and adults who:
- Are ages 0 to 60 years old
- Are candidates for an allogeneic hematopoietic stem cell transplant for acute lymphocytic leukemia, acute myeloid leukemia, or chronic myelogenous leukemia
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
You can read about the study protocol on clinicaltrials.gov.
Who can I contact for more information?
Please email the research coordinator for more information about this study.